Cambridge Investment Research Advisors Inc. Has $972,000 Stock Position in Encompass Health Corporation (NYSE:EHC)

Cambridge Investment Research Advisors Inc. grew its stake in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 30.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 9,597 shares of the company's stock after acquiring an additional 2,218 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in Encompass Health were worth $972,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Sivik Global Healthcare LLC lifted its holdings in shares of Encompass Health by 14.7% in the first quarter. Sivik Global Healthcare LLC now owns 51,600 shares of the company's stock valued at $5,226,000 after purchasing an additional 6,600 shares in the last quarter. Nilsine Partners LLC acquired a new stake in Encompass Health in the first quarter valued at approximately $2,778,000. Blue Trust Inc. boosted its stake in shares of Encompass Health by 35.1% during the 1st quarter. Blue Trust Inc. now owns 1,990 shares of the company's stock worth $202,000 after acquiring an additional 517 shares in the last quarter. Guided Capital Wealth Management LLC acquired a new position in Encompass Health during the first quarter valued at approximately $2,096,000. Finally, State of Alaska Department of Revenue raised its position in shares of Encompass Health by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 13,006 shares of the company's stock valued at $1,316,000 after purchasing an additional 315 shares during the period. 97.25% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on EHC shares. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective on the stock in a research note on Thursday, June 5th. UBS Group upped their target price on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. Barclays increased their price objective on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Truist Financial reiterated a "buy" rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Finally, KeyCorp upped their price target on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 27th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $127.00.

Insider Buying and Selling

In other news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the transaction, the executive vice president directly owned 79,710 shares of the company's stock, valued at $9,149,910.90. This represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark J. Tarr sold 118,384 shares of Encompass Health stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the sale, the chief executive officer owned 527,070 shares in the company, valued at $64,054,817.10. This trade represents a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,663 shares of company stock valued at $16,034,082. Company insiders own 2.10% of the company's stock.

Encompass Health Trading Up 0.2%

EHC traded up $0.18 during trading on Monday, reaching $119.22. 647,780 shares of the company's stock were exchanged, compared to its average volume of 702,366. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a fifty-two week low of $82.74 and a fifty-two week high of $123.13. The company's fifty day moving average price is $119.39 and its 200-day moving average price is $105.53. The firm has a market capitalization of $12.02 billion, a PE ratio of 24.63, a P/E/G ratio of 2.42 and a beta of 0.88.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter last year, the firm earned $1.12 EPS. Encompass Health's quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities analysts forecast that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. Encompass Health's payout ratio is 14.05%.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.